As a result of attending this program, participants will be able to:
- Evaluate new evidence guiding initial ART selection across different baseline viral loads and CD4 counts.
- Assess emerging once-weekly oral ART strategies and their potential role in HIV treatment.
- Interpret new evidence supporting long-acting injectable ART in adolescents and people with adherence or engagement challenges.
- Apply efficacy, resistance, safety, and monitoring data when selecting and managing long-acting ART.
- Evaluate longer-term efficacy, safety, adherence, and acceptability data for twice-yearly lenacapavir PrEP.
- Compare emerging implementation considerations for long-acting lenacapavir and cabotegravir PrEP.
- Describe recent advances in HIV remission research and their implications for future cure strategies.
Featured Presenter:
William Mazur, MD- Medical Director, Holloway Community Program
